ANI Pharmaceuticals (ANIP) Earning Somewhat Positive Media Coverage, Study Shows

News coverage about ANI Pharmaceuticals (NASDAQ:ANIP) has trended somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. ANI Pharmaceuticals earned a news sentiment score of 0.10 on Accern’s scale. Accern also assigned news stories about the specialty pharmaceutical company an impact score of 45.7235207981644 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Shares of ANI Pharmaceuticals (NASDAQ:ANIP) opened at $71.06 on Friday. ANI Pharmaceuticals has a fifty-two week low of $42.23 and a fifty-two week high of $74.70. The stock has a market capitalization of $827.35, a PE ratio of 112.79 and a beta of 2.90. The company has a quick ratio of 2.39, a current ratio of 3.45 and a debt-to-equity ratio of 0.83.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.99 by $0.12. The company had revenue of $48.16 million during the quarter, compared to the consensus estimate of $48.12 million. ANI Pharmaceuticals had a return on equity of 22.40% and a net margin of 4.45%. The company’s revenue for the quarter was up 25.0% compared to the same quarter last year. During the same period in the prior year, the company earned $1.09 earnings per share. sell-side analysts predict that ANI Pharmaceuticals will post 3.59 EPS for the current fiscal year.

Several equities research analysts have issued reports on the company. ValuEngine upgraded ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, November 25th. BidaskClub upgraded ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, January 5th. Canaccord Genuity set a $75.00 price target on ANI Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, December 9th. Zacks Investment Research downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, January 2nd. Finally, TheStreet upgraded ANI Pharmaceuticals from a “c+” rating to a “b” rating in a report on Thursday, November 16th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $71.00.

WARNING: This report was originally posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this report on another site, it was illegally copied and reposted in violation of US and international trademark and copyright law. The correct version of this report can be viewed at https://www.themarketsdaily.com/2018/01/12/ani-pharmaceuticals-anip-earning-somewhat-positive-media-coverage-study-shows.html.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Insider Buying and Selling by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply